Save Product
Product Details
Source
The antibody is isolated from the serum of COVID-19 vaccine recipient and is recombinantly expressed in HEK293 cells. This antibody can broadly neutralize SARS-CoV-2 Variants of Concerns (VOCs) including Alpha, Beta, Gamma, Delta and Omicron.
Antibody Type
Recombinant Monoclonal
Clone
AM359b
Isotype
Human IgG4, Kappa
Host Species
Human
Specificity
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. Cross-reactivity with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1 has not been tested.
Application
ApplicationRecommended Use / PerformanceELISA0.2-2 μg/mLPurification
Protein A purified.
Aggregation
Less than 10%, as determined by SEC-MALS.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized SARS-CoV-2 Spike Trimer, His Tag (B.1.1.529/Omicron) (Cat. No. SPN-C52Hz) at 2μg/mL (100μL/well) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (Cat. No. SPD-M402a) with a linear range of 0.2-6 ng/mL (QC tested).
Protocol
Immobilized SARS-CoV-2 Spike RBD, His Tag (B.1.1.529/Omicron) (Cat. No. SPD-C522e) at 2μg/mL (100μL/well) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (Cat. No. SPD-M402a) with a linear range of 0.1-3 ng/mL (Routinely tested).
Protocol
Immobilized SARS-CoV-2 Spike protein WT (Cat. No. SPN-C52H9), Alpha (Cat. No. SPN-C52H6), Beta (Cat. No. SPN-C52Hk),Gamma (Cat. No. SPN-C52Hg), Delta (Cat. No. SPN-C52He) and Omicron (Cat. SPN-C52Hz) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (Cat. No. SPD-M402a) with a linear range of 0.20-6.25 ng/mL (Routinely tested).
Protocol
Immobilized SARS-CoV-2 Spike RBD WT (Cat. No. SPD-C52H1), Delta (Cat. No. SPD-C52Hh) and Omicron (Cat. SPD-C522e) can bind Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (Cat. No. SPD-M402a) with a linear range of 0.20-6.25 ng/mL (Routinely tested).
Protocol
Anti-SARS-CoV-2 Spike RBD Broadly Neutralizing Antibody, Human IgG4 (AM359b) (Cat.No. SPD-M402a) neutralizes SARS-CoV-2 Spike Trimer by inhibiting Spike: ACE2 interaction. The Wild type (WT) Spike Trimer or Alpha, Delta, B.1.1.529/Omicron, BA.2/Omicron, BA.3/Omicron mutant-coated plate is incubated with the Biotinylated Human ACE2 / ACEH Protein and treated with the neutralizing antibody at increasing concentration . Percent inhibition is calculated based on the OD value.
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
